Form 4: BridgeBio Pharma CFO Brian Stephenson Reports Stock Transactions

Brian Stephenson, CFO of BridgeBio Pharma, reports the vesting and subsequent tax withholding of shares related to restricted stock units.

Summary

• On May 16, 2024, Brian Stephenson, the Secretary, Treasurer, and CFO of BridgeBio Pharma, Inc., engaged in transactions involving the company's common stock and restricted stock units (RSUs).
• Stephenson acquired 27,507 shares of common stock through the vesting of RSUs.
• A total of 13,943 shares were withheld to satisfy tax obligations at a price of $31.04 per share.
• Following these transactions, Stephenson directly owns 76,472 shares of BridgeBio Pharma's common stock.
• The reported transactions also involve the vesting of various tranches of RSUs, which convert into common stock.
• The vesting schedules for these RSUs are based on continued service with the Issuer or its subsidiaries.

Sentiment

Score: 5

Explanation: This is a routine disclosure of stock transactions by a company insider, and doesn't inherently indicate positive or negative sentiment. It's a neutral event.

Future Outlook

The vesting of RSUs is contingent upon continued service with BridgeBio Pharma or its subsidiaries.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like the CFO, trade their company's stock. This provides transparency to the market.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units (RSUs) that vest over time, aligning executive interests with long-term shareholder value.
• Tax withholding upon vesting of RSUs is a standard practice across publicly traded companies.
• Comparable companies such as Amgen, Biogen, and Gilead Sciences also have executives who regularly report stock transactions via Form 4 filings.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect standard executive compensation practices.
• Employees holding RSUs are affected by the vesting schedules and tax implications.

Key Dates